The Lancet Neurology 2019

4 papers
In 2019, *The Lancet Neurology* featured research centered on clinical trial outcomes for multiple sclerosis, acute stroke interventions, and traumatic brain injury (TBI). A primary focus was the evaluation of therapeutic efficacy and patient prognosis. Key publications included the SYNERGY trial, which investigated opicinumab for relapsing multiple sclerosis, and the CENTER-TBI study, a multicentre longitudinal analysis of care pathways and outcomes for TBI patients in Europe. Vascular neurology was another major theme, with studies addressing both treatment protocols and risk assessment. The BEST trial provided a comparative analysis of endovascular versus standard medical treatment for vertebrobasilar artery occlusion. Additionally, research into cerebral microbleeds utilized pooled data from cohort studies to determine stroke risk following ischemic events or transient ischaemic attacks. Prolific authors contributing to these areas included Thomas Leung, Aaron Deykin, and Abdullatif Al Khedr.

Top Research Directions

The 4 research directions with The Lancet Neurology 2019 papers, ranked by paper count, next to 2017. Share is the fraction of the edition’s papers in the direction.

#Direction20192017Share 2019Share 20172017 rank
1Leave One Out Sensitivity Analysis1025.0%0.0%—
2Predicting Hemorrhagic Transformation Risk in Acute Stroke Reperfusion1025.0%0.0%—
3Proportional Hazards Modeling for Survival Analysis1025.0%0.0%—
4Tracking Systemic Atherosclerosis Across Vascular Beds1025.0%0.0%—

Download all directions as CSV

Institutions

Institutions credited by The Lancet Neurology 2019 papers: a paper credits every institution named in its affiliations, once. 25 institutions share 1 credited papers.

#InstitutionPapersShare20172017 rank
100y8ke806 1100.0%0—
201141nq92 1100.0%0—
301v55qb38 1100.0%0—
402mqtne57 1100.0%0—
50370htr03 1100.0%0—
603yr0pg70 1100.0%0—
7048b34d51 1100.0%0—
804ngysf93 1100.0%0—
9059n1d175 1100.0%0—
1005mhswc23 1100.0%0—
11Assistance Publique – Hôpitaux de Paris 1100.0%0—
12Chinese University of Hong Kong 1100.0%0—
13Ewha Womans University 1100.0%0—
14Harvard Medical School 1100.0%0—
15Heidelberg University 1100.0%0—
16Inserm 1100.0%16
17Massachusetts General Hospital 1100.0%0—
18Seoul National University 1100.0%0—
19Seoul National University Bundang Hospital 1100.0%0—
20University College London 1100.0%0—
21University Hospital Heidelberg 1100.0%0—
22University Medical Centre Mannheim 1100.0%0—
23University of Hong Kong 1100.0%0—
24University of Oxford 1100.0%0—
25Yonsei University 1100.0%0—

Download all institutions as CSV

About this data

Papers. The Lancet Neurology 2019 lists 4 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2017 use shares, since the edition went from 5 to 4 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 4 papers (25.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-19 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “The Lancet Neurology 2019”, https://lacuna.tiptreesystems.com/venue/the-lancet-neurology/2019.

Top Authors

AuthorPapers
Christopher Li Hsian Chen1

Impactful Papers

Papers from The Lancet Neurology 2019 that shaped research clusters.

Foundational

Influential

Papers

Title
Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study
Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies
Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial